These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Trial watch: ipilimumab success in melanoma provides boost for cancer immunotherapy. Nat Rev Drug Discov; 2010 Aug; 9(8):584. PubMed ID: 20671754 [No Abstract] [Full Text] [Related]
5. [Nivolumab for metastatic melanoma-basic knowledge and clinical data]. Yamazaki N; Maeda Y Gan To Kagaku Ryoho; 2015 Apr; 42(4):434-8. PubMed ID: 26020984 [No Abstract] [Full Text] [Related]
6. Melanoma drug wins US approval. Ledford H Nature; 2011 Mar; 471(7340):561. PubMed ID: 21455150 [No Abstract] [Full Text] [Related]
7. Update on the role of ipilimumab in melanoma and first data on new combination therapies. Maio M; Di Giacomo AM; Robert C; Eggermont AM Curr Opin Oncol; 2013 Mar; 25(2):166-72. PubMed ID: 23299197 [TBL] [Abstract][Full Text] [Related]
8. Strides in melanoma announced: maximizing value comes next. Tuma RS J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727 [No Abstract] [Full Text] [Related]
9. Pembrolizumab superior to ipilimumab in melanoma. Cancer Discov; 2015 Jun; 5(6):568. PubMed ID: 25895921 [TBL] [Abstract][Full Text] [Related]
10. Beyond ipilimumab: new approaches target the immunological synapse. Garber K J Natl Cancer Inst; 2011 Jul; 103(14):1079-82. PubMed ID: 21737695 [No Abstract] [Full Text] [Related]
11. Immunotherapy: Combined immunotherapy--a new standard in metastatic melanoma? Hauschild A; Garbe C Nat Rev Clin Oncol; 2015 Aug; 12(8):439-40. PubMed ID: 26099985 [No Abstract] [Full Text] [Related]
12. Herceptin produces clinical benefit in metastatic breast cancer regardless of tumor response. Oncology (Williston Park); 2004 Aug; 18(9):1201. PubMed ID: 15471203 [No Abstract] [Full Text] [Related]
13. CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma. Tarhini AA; Kirkwood JM Oncology (Williston Park); 2010 Dec; 24(14):1302, 1304. PubMed ID: 21294474 [No Abstract] [Full Text] [Related]